Secura Bio
Oncology Therapeutics · Prescription Drugs
2open roles
$226kmedian advertised pay
50+people
2019founded
Jobs
$172k – $210k per year · Remote (United States) · Full-Time · 8+ years exp · Bachelor's Degree
Veeva
Apply
$196k – $239k per year · Remote (United States) · Full-Time · 8+ years exp · Master's Degree
Apply
Salary insights
Compensation ranges based on this company's open jobs
Median
$226k
Typical range
$154k – $239k
Open positions
5
3
Jobs
Senior
33.3%
Staff
33.3%
Architect
33.3%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Senior | 1 | $154k | $154k |
| Staff | 1 | $239k | $239k |
| Architect | 1 | $210k | $210k |
Highest paying role
Medical Science Liaison (MSL) - Midwest
$239k
Normalized to USD per year
All salaries at Secura Bio
By role, level and city, against the market · 5 jobs with pay
Growth
Hiring Momentum
47/100
Stable
Open positions
5
2 opened / 1 closed in 30 days
Median time-to-fill
57 days
faster than 23% of the market
ATS activity
Every ~5 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Marketing
50% ▲
Biotech
33% ▼
Finance
17% ▲
Activity Timeline
Added Microsoft Excel to stack
Oct 2026
People
Mark Spring
Executive Officer, Director
Brett Lund
Executive Officer, Director
Joseph Limber
Executive Officer, Director
Juan Estruch
Executive Officer
Jeffrey Ferrell
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Tech stack
Technologies named in job postings at Secura Bio over the last 12 months, by layer, with the share of postings for each.
Technologies in use
2
Postings analysed
2
Stack modernity
53/100
Developer tools
Microsoft Excel
Veeva
Sign in to see how your skills match this stack
Sign In
News
Secura Bio Expands Chief Financial Officer Will Brown's Leadership Role to Include Chief Operating Officer
Read more
Report
Secura Bio Announces Poster Presentation Highlighting Extended Follow Up Analyses from Phase 2 PRIMO Trial at the 2025 American Society of Hematology Meeting
Read more
Report
Secura Bio Announces First Patient Dosed in Phase 3 TERZO Study of COPIKTRA (duvelisib) in Relapsed/Refractory Nodal T-follicular Helper Cell Lymphoma
Interim data from the first phase 3 study of a PI3K inhibitor to treat relapsed or refractory nodal T-follicular helper cell lymphoma (nTFHL) anticipated in early-2027SUMMERLIN, Nev., June 09, 2025 (GLOBE NEWSWIRE) -- Secura Bio, Inc. (www.securabio.com),
Read more
Report
Secura Bio Presented New Data From Its Phase 2 PRIMO Trial Of Copiktra (Duvelisib) In Relapsed Or Refractory Peripheral T-Cell Lymphoma And Announced Plans For Its Phase 3 TERZO Trial At The 2024 American Society Of Hematology Meeting
Secura Bio Presented New Data From Its Phase 2 PRIMO Trial Of Copiktra (Duvelisib) In Relapsed Or Refractory Peripheral T-Cell Lymphoma And Announced Plans For Its Phase 3 TERZO Trial At The 2024 Ame.... Data from the Phase 2 PRIMO trial in 123 patients s
Read more
Report
Secura Bio Announces the Addition of Two New Board of Directors Members
/PRNewswire/ -- Secura Bio, Inc. (Secura Bio) - (www.securabio.com), an integrated pharmaceutical company dedicated to the worldwide development and...
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Berkeley Heights
United States
HQ
Secura Bio, Inc.®
50-200 est. staff
Suite 1100, Berkeley Heights, New Jersey 07922